Seer, Inc. (NASDAQ:SEER) Short Interest Up 126.6% in February

Seer, Inc. (NASDAQ:SEER) was the target of a significant increase in short interest in February. As of February 13th, there was short interest totaling 634,111 shares, an increase of 126.6% from the January 29th total of 279,780 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 352,140 shares, the days-to-cover ratio is currently 1.8 days. Based on an average daily trading volume, of 352,140 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.3% of the shares of the stock are sold short.

Key Headlines Impacting Seer

Here are the key news stories impacting Seer this week:

• Positive Sentiment: Q4 EPS beat and improving operating metrics: Seer reported GAAP Q4 EPS of ($0.29), beating consensus by $0.03, with gross margin ~52% and a narrowing net loss vs. prior year — signs of progress on cost reduction. Press Release
• Positive Sentiment: Installed base and scientific validation: Installed base expanded to 82 instruments (67% YoY growth) and customer studies were published in top journals, supporting commercial adoption of the Proteograph platform. Quiver Quant Summary
• Positive Sentiment: Shareholder protections and buyback: Board adopted an NOL preservation plan to protect ~$262M of tax assets (reduces future tax risk) and Seeking Alpha noted a new buyback approval — both can be supportive for long‑term value. NOL Plan Buyback Article
• Neutral Sentiment: Solid cash runway: Seer reported approximately $240.6M in cash, cash equivalents and investments at year‑end, providing runway to execute product development and commercialization plans. Press Release
• Negative Sentiment: Conservative 2026 revenue guidance — big miss vs. Street: Management guided FY‑2026 revenue of $16.0–$18.0M vs. consensus ~ $22.1M, implying only ~3% growth at the midpoint versus 2025 — the primary catalyst for the share decline. Guidance Press Release
• Negative Sentiment: Revenue miss and continued losses: Q4 revenue was $4.2M (below some analyst estimates of $4.6M) and FY‑2025 net loss remained sizable ($73.6M), highlighting ongoing path‑to‑profitability risk. Press Release
• Negative Sentiment: Demand headwinds and market skepticism: Management cited customer budget pressures and NIH funding uncertainty; short interest jumped ~126.6% in February, indicating increased bearish positioning. Quiver Quant / Short Interest

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SEER. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Seer to a “hold” rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of Seer

Institutional investors have recently modified their holdings of the company. Occudo Quantitative Strategies LP purchased a new position in Seer during the 2nd quarter valued at about $25,000. Quadrature Capital Ltd bought a new stake in shares of Seer in the 2nd quarter worth approximately $47,000. Marshall Wace LLP purchased a new position in shares of Seer during the fourth quarter valued at approximately $85,000. Barclays PLC increased its stake in shares of Seer by 685.0% during the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares during the period. Finally, Corient Private Wealth LLC bought a new position in shares of Seer during the fourth quarter valued at approximately $116,000. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

Seer Stock Performance

Shares of SEER stock opened at $1.72 on Friday. The company has a market capitalization of $95.96 million, a P/E ratio of -1.34 and a beta of 1.63. Seer has a fifty-two week low of $1.62 and a fifty-two week high of $2.41. The stock has a 50 day moving average price of $1.89 and a two-hundred day moving average price of $2.02.

Seer (NASDAQ:SEER) last issued its earnings results on Thursday, February 26th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. Seer had a negative net margin of 443.96% and a negative return on equity of 25.35%. The company had revenue of $4.20 million for the quarter, compared to the consensus estimate of $4.60 million. As a group, equities analysts predict that Seer will post -1.42 earnings per share for the current year.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.